First Amendment to the License AgreementLicense Agreement • October 27th, 2016 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This First Amendment to the License Agreement (the “First Amendment”) is made and entered into as of September 20, 2016 (the “First Amendment Effective Date”) by and between Sangamo BioSciences, Inc., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and Open Monoclonal Technology, Inc., a Delaware corporation with offices at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121 (“OMT”). OMT and Sangamo are individually referred to herein as a “Party” or collectively as the “Parties”.
ContractResearch and Commercial License Option Agreement • October 27th, 2016 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
